Sign up
Pharma Capital

IXICO sees contracts' value increased by around £500,000

IXICO's analysis technology is being used by a US biopharma for a phase II trial of a new treatment for Huntington’s disease and by a different company for a Phase II/III clinical trial contract in Alzheimer's disease; the scope of both contracts has been extended
Alzheimer's sufferer
IXICO's neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, Parkinson's disease

IXICO Plc (LON:IXI), the digital technologies company serving neuroscience, has signed amendments to current contracts that expand the clinical trial services provided to two biopharmaceutical companies.

The change orders have increased the combined contracts’ value by £500,000 or roughly 24% to £2.35mln.

READ IXICO PLC technology to be used in Alzheimer's clinical trial​

IXICO said the changes reflect an expansion in the scope of PET and MRI neuroimaging clinical trial services, with IXICO providing additional specialist services during the contract period.

The Phase II study contracts in Alzheimer's disease and Huntington's disease were previously announced in July and September 2017, respectively.

The scope of services that IXICO provides can be expanded or extended at any time during the life of a clinical trial, so change orders can occur during the course of multi-year contracts, IXICO explained.

Giulio Cerroni, the chief executive officer of IXICO, expressed delight at the extension of the two contracts.

“This underscores the importance of working closely with our biopharmaceutical clients, particularly during the initial phase of a contract, to maximise the value our specialist technologies and services can provide," he added.  

John-H.jpg
Why Invest In IXICO Plc? Read More Here

Register here to be notified of future IXI Company articles
View full IXI profile View Profile
Article

IXICO bags a £1mln contract

View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.